Heathbridge Capital Management Ltd. Sells 16,100 Shares of Haleon plc (NYSE:HLN)

Heathbridge Capital Management Ltd. cut its stake in Haleon plc (NYSE:HLN) by 1.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,109,300 shares of the company’s stock after selling 16,100 shares during the quarter. Haleon comprises approximately 4.2% of Heathbridge Capital Management Ltd.’s holdings, making the stock its 11th largest holding. Heathbridge Capital Management Ltd.’s holdings in Haleon were worth $10,583,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in HLN. FMR LLC lifted its position in shares of Haleon by 5.8% during the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock worth $1,110,035,000 after purchasing an additional 5,768,117 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Haleon by 49.9% in the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock valued at $96,833,000 after acquiring an additional 3,046,841 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Haleon by 25.3% in the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock valued at $53,791,000 after acquiring an additional 1,026,939 shares in the last quarter. Natixis Advisors LLC raised its holdings in shares of Haleon by 142.5% in the third quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock valued at $15,593,000 after acquiring an additional 866,070 shares in the last quarter. Finally, Van ECK Associates Corp raised its holdings in shares of Haleon by 13.5% in the fourth quarter. Van ECK Associates Corp now owns 3,509,400 shares of the company’s stock valued at $33,480,000 after acquiring an additional 418,609 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors.

Haleon Price Performance

HLN opened at $9.71 on Friday. The business’s 50-day moving average is $9.54 and its two-hundred day moving average is $9.80. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The firm has a market capitalization of $43.93 billion, a PE ratio of 28.54, a price-to-earnings-growth ratio of 2.70 and a beta of 0.28.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HLN. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Haleon has a consensus rating of “Moderate Buy” and an average price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.